Status:
COMPLETED
Effectiveness and Safety of the COVID-19 Vaccination for Patients With Liver Disease (CHESS2101)
Lead Sponsor:
Hepatopancreatobiliary Surgery Institute of Gansu Province
Collaborating Sponsors:
LanZhou University
Huashan Hospital
Conditions:
COVID-19
Liver Disease
Eligibility:
All Genders
18+ years
Brief Summary
COVID-19 pandemic with SARS-CoV-2 infection has become a global challenge. Though most cases of COVID-19 are mild, the disease can also be fatal. Patients with liver disease are more susceptible to da...
Detailed Description
Patients with liver disease, especially liver cirrhosis, hepatobiliary malignancies, candidates for liver transplantation, and individuals who are immunosuppressed after liver transplantation, have an...
Eligibility Criteria
Inclusion
- Clinically or pathologically diagnosed with pre-existing liver disease, including: chronic liver disease, cirrhosis, liver cancer, liver transplant subjects, etc.;
- Receiving the whole-course COVID-19 vaccination for 14 days or more;
- Volunteer to participate in this study.
Exclusion
- Younger than 18 years old;
- Women during pregnancy or lactation;
- Research on other situations deemed unsuitable for selection.
Key Trial Info
Start Date :
May 11 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04883177
Start Date
May 11 2021
End Date
May 1 2022
Last Update
April 25 2023
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
2
Beijing You'an Hospital
Beijing, Beijing Municipality, China
3
Chongqing Fuling Central Hospital
Chongqing, Chongqing Municipality, China
4
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China